ATE270324T1 - Methoden zur erhöhung der effizienz rekombinanter aav produkte - Google Patents

Methoden zur erhöhung der effizienz rekombinanter aav produkte

Info

Publication number
ATE270324T1
ATE270324T1 AT98915603T AT98915603T ATE270324T1 AT E270324 T1 ATE270324 T1 AT E270324T1 AT 98915603 T AT98915603 T AT 98915603T AT 98915603 T AT98915603 T AT 98915603T AT E270324 T1 ATE270324 T1 AT E270324T1
Authority
AT
Austria
Prior art keywords
methods
aav
production
expression
compositions
Prior art date
Application number
AT98915603T
Other languages
English (en)
Inventor
Richard J Samulski
Xiao Xiao
Richard Snyder
Original Assignee
Cell Genesys Inc
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc, Univ North Carolina filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of ATE270324T1 publication Critical patent/ATE270324T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98915603T 1997-04-14 1998-04-14 Methoden zur erhöhung der effizienz rekombinanter aav produkte ATE270324T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4354797P 1997-04-14 1997-04-14
PCT/US1998/007654 WO1998046728A1 (en) 1997-04-14 1998-04-14 Methods for increasing the efficiency of recombinant aav product

Publications (1)

Publication Number Publication Date
ATE270324T1 true ATE270324T1 (de) 2004-07-15

Family

ID=21927717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98915603T ATE270324T1 (de) 1997-04-14 1998-04-14 Methoden zur erhöhung der effizienz rekombinanter aav produkte

Country Status (10)

Country Link
US (2) US6548286B1 (de)
EP (1) EP1007637B1 (de)
JP (2) JP4135120B2 (de)
AT (1) ATE270324T1 (de)
AU (1) AU728220B2 (de)
CA (1) CA2287478C (de)
DE (1) DE69824859T2 (de)
ES (1) ES2224375T3 (de)
NZ (1) NZ500546A (de)
WO (1) WO1998046728A1 (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046728A1 (en) * 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US6989264B2 (en) * 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
JP2003511037A (ja) * 1999-10-01 2003-03-25 ジェノボ， インコーポレイテッド ＡＡＶｒｅｐ／ｃａｐ遺伝子を含むアデノウイルスを使用する組換えＡＡＶの産生
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
JP2002153278A (ja) * 2000-11-22 2002-05-28 Hisamitsu Pharmaceut Co Inc ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP1636360A4 (de) * 2003-06-03 2006-11-08 Cell Genesys Inc Zusammensetzungen und verfahren zur verstärkten expression rekombinanter polypeptide von einem vektor unter verwendung einer peptidspaltstelle
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
JP4773424B2 (ja) 2004-03-19 2011-09-14 イエール ユニバーシティ レナラーゼ（モノアミンオキシダーゼｃ）の検出、単離及び使用
WO2006033689A2 (en) * 2004-06-18 2006-03-30 The University Of Montana Aav mediated gene delivery to cochlear cells
US7714119B2 (en) * 2004-07-13 2010-05-11 Biosante Pharmaceuticals, Inc. AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
US20060293264A1 (en) * 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
RU2478709C2 (ru) 2005-07-21 2013-04-10 Эбботт Лэборетриз ЭКСПРЕССИЯ МНОЖЕСТВА ГЕНОВ, ВКЛЮЧАЯ sORF-КОНСТРУКЦИИ, И СПОСОБЫ ЭКСПРЕССИРОВАНИЯ ИММУНОГЛОБУЛИНА
EP1981548A4 (de) * 2006-01-20 2010-03-24 Univ North Carolina Verstärkte produktion von infektiösen parvovirus-vektoren in insektenzellen
EP2013348A4 (de) 2006-03-30 2009-09-02 Univ California Verfahren und zusammensetzungen für lokalisierte sekretion von anti-ctla-4-antikörpern
EP2007795B1 (de) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav-capsid-proteine
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
CN104087591A (zh) 2006-06-19 2014-10-08 阿斯克肋匹奥生物制药公司 用于基因治疗的修饰的因子viii和因子ix基因和载体
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
AU2008350903B2 (en) * 2008-02-19 2015-04-02 Sardocor Corp. Compositions for enhanced uptake of viral vectors in the myocardium
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
US20120172419A1 (en) 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
CA2776990A1 (en) * 2009-10-30 2011-05-05 Abbott Laboratories Sorf constructs and multiple gene expression
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
JP5922095B2 (ja) 2010-03-29 2016-05-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 薬理学的に誘導される導入遺伝子アブレーション系
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
CN104159601B (zh) 2012-02-01 2017-05-24 代表亚利桑那大学的亚利桑那董事会 弯曲杆菌属免疫原性组合物及其用途
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP3008191A2 (de) * 2013-06-13 2016-04-20 Shire Human Genetic Therapies, Inc. Virenproduktion auf messenger-rna-basis
CN105705140A (zh) 2013-11-05 2016-06-22 克隆技术实验室有限公司 干转染组合物及其制备和使用方法
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
EP3778627A1 (de) 2014-03-09 2021-02-17 The Trustees of The University of Pennsylvania Zusammensetzungen für die behandlung des mangels von ornithin-transcarbamylase (otc)
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
BR112016024379A2 (pt) 2014-04-25 2017-10-10 Univ Pennsylvania variantes ldlr e seu uso em composições para reduzir os níveis de colesterol
JP6983511B2 (ja) 2014-04-25 2021-12-17 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 脳中の転移乳癌および他の癌を処置するための方法および組成物
EP3142750B1 (de) 2014-05-13 2020-07-01 The Trustees Of The University Of Pennsylvania Zusammensetzungen mit aav-expression von zwei antikörperkonstrukten und verwendungen davon
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
EP3978614A3 (de) 2015-01-07 2022-07-27 Universitat Autònoma de Barcelona Einzelvektor-genkonstrukt mit insulin und glucokinasegenen
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
EP3256487A4 (de) 2015-02-09 2018-07-18 Duke University Zusammensetzungen und verfahren zur epigenombearbeitung
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
JP6851319B2 (ja) 2015-04-27 2021-03-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒト疾患のＣＲＩＳＰＲ／Ｃａｓ９媒介性の修正のためのデュアルＡＡＶベクター系
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
ES3009026T3 (en) 2015-07-22 2025-03-25 Univ Duke High-throughput screening of regulatory element function with epigenome editing technologies
CN108368521A (zh) 2015-08-06 2018-08-03 宾夕法尼亚州大学信托人 Glp-1和其在用于治疗代谢疾病的组合物中的用途
JP6905755B2 (ja) 2015-08-25 2021-07-21 デューク ユニバーシティ Ｒｎａガイド型エンドヌクレアーゼを使用してゲノム工学における特異性を改善する組成物および方法
JP6877408B2 (ja) 2015-08-31 2021-05-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ペット治療用ａａｖ−ｅｐｏ
JP6933379B2 (ja) 2015-09-24 2021-09-08 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 転移を低減するための方法および組成物
WO2017053732A2 (en) 2015-09-24 2017-03-30 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
WO2017062750A1 (en) 2015-10-09 2017-04-13 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating stargardt's disease and other ocular disorders
EP4089175A1 (de) 2015-10-13 2022-11-16 Duke University Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
AU2016344065A1 (en) 2015-10-28 2018-05-10 The Trustees Of The University Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
EP4085934A1 (de) 2015-12-11 2022-11-09 The Trustees of The University of Pennsylvania Gentherapeutische behandlung der familiären hypercholesterinämie
AU2016370590B2 (en) 2015-12-14 2023-11-02 The Trustees Of The University Of Pennsylvania Composition for treatment of Crigler-Najjar syndrome
MX2018007230A (es) 2015-12-14 2018-11-09 Univ Pennsylvania Terapia genica para trastornos oculares.
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP4049683A1 (de) 2016-04-29 2022-08-31 Adverum Biotechnologies, Inc. Evasion von neutralisierenden antikörpern durch ein rekombinantes adeno-assoziiertes virus
JP7101656B2 (ja) 2016-07-08 2022-07-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｒｄｈ１２が関与する疾患及び疾病を治療する方法及び組成物
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
WO2018022511A1 (en) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
EP3500278B1 (de) 2016-08-19 2024-05-22 University of Florida Research Foundation, Incorporated Zusammensetzungen zur behandlung von erkrankungen mit rekombinantem selbstkomplementärem adeno-assoziiertem virus
EP3528785A4 (de) 2016-10-19 2020-12-02 Adverum Biotechnologies, Inc. Modifizierte aav-kaspide und verwendungen davon
WO2018100054A1 (en) 2016-12-01 2018-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of retinal degenerative diseases
CA3046347A1 (en) 2016-12-07 2018-06-14 University Of Florida Research Foundation, Incorporated Il-1ra cdnas
EP3595688A4 (de) 2017-02-20 2020-12-30 The Trustees Of The University Of Pennsylvania Gentherapie zur behandlung familiärer hypercholesterinämie
TW201837170A (zh) 2017-02-28 2018-10-16 賓州大學委員會 新穎ａａｖ媒介的流感疫苗
CA3053399A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Novel adeno-associated virus (aav) clade f vector and uses therefor
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
KR102545070B1 (ko) 2017-03-01 2023-06-19 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 안구 장애에 대한 유전자 치료
JP7343903B2 (ja) 2017-03-17 2023-09-13 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 遺伝子発現増強のための組成物および方法
GB201706090D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Methods for adeno-associated viral vector production
CA3058970A1 (en) 2017-04-18 2018-10-25 Glaxosmithkline Intellectual Property Development Limited Methods for adeno-associated viral vector production
US11879133B2 (en) 2017-04-24 2024-01-23 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
IL270422B2 (en) 2017-05-11 2025-04-01 Univ Pennsylvania Gene therapy for neuronal ceroid lipofuscinosis
KR102765034B1 (ko) 2017-05-24 2025-02-11 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
MX2019013982A (es) 2017-05-24 2020-07-22 Univ Autonoma De Barcelona Star Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21).
WO2018218359A1 (en) 2017-05-31 2018-12-06 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
US11827898B2 (en) 2017-06-14 2023-11-28 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
EP3954766A1 (de) 2017-10-10 2022-02-16 NantBio, Inc. Modifizierte ec7-zellen mit geringer toxizität für virale produktionslasten
MY207644A (en) 2017-12-19 2025-03-07 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
KR102848518B1 (ko) 2018-02-27 2025-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 캡시드 탈아미드화가 감소된 신규 아데노-연관 바이러스(aav) 벡터 및 이의 용도
AU2019351815A1 (en) 2018-10-01 2021-05-06 The Trustees Of The University Of Pennsylvania Compositions useful for treating GM1 gangliosidosis
CN113227126A (zh) 2018-11-26 2021-08-06 巴塞罗那自治大学 成纤维细胞生长因子21(fgf21)基因治疗
GB201901571D0 (en) 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
SG11202108504YA (en) 2019-02-22 2021-09-29 Univ Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
SG11202108480UA (en) 2019-02-26 2021-09-29 Univ Pennsylvania Compositions useful in treatment of krabbe disease
WO2020180886A1 (en) 2019-03-04 2020-09-10 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the akt pathway
KR20220020261A (ko) 2019-05-03 2022-02-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 이염성 백질이영양증의 치료에 유용한 조성물
KR20220016100A (ko) 2019-05-31 2022-02-08 유니버시타트 아우토노마 데 바르셀로나 인슐린 유전자 요법
EP3914720B9 (de) 2019-07-10 2023-09-27 Masonic Medical Research Laboratory Vgll4 mit ucp-1-cis-regulierendem element und verfahren zu dessen verwendung
US10557149B1 (en) * 2019-07-15 2020-02-11 Vigene Biosciences, Inc. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
US20220396806A1 (en) 2019-07-26 2022-12-15 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
AU2020401116A1 (en) 2019-12-10 2022-07-21 Takeda Pharmaceutical Company Limited Adeno associated virus vectors for the treatment of Hunter disease
US20230201372A1 (en) 2020-05-13 2023-06-29 Akouos, Inc. Compositions and methods for treating slc26a4-associated hearing loss
JP2023528590A (ja) 2020-05-26 2023-07-05 ウニベルシダッド アウトノマ デ バルセロナ 中枢神経系障害に対する線維芽細胞増殖因子２１（ｆｇｆ２１）遺伝子治療
AU2021332235A1 (en) 2020-08-24 2023-03-23 The Trustees Of The University Of Pennsylvania Viral vectors encoding GLP-1 receptor agonist fusions and uses thereof in treating metabolic diseases
AR123358A1 (es) 2020-08-26 2022-11-23 Univ Pennsylvania Virus adenoasociado recombinante para el tratamiento de la neurodegeneración de inicio adulto asociada a la grn
CA3197342A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Gene therapy for ocular manifestations of cln2 disease
GB202016254D0 (en) * 2020-10-13 2020-11-25 Freeline Therapeutics Ltd Plasmid system
AU2021359874A1 (en) 2020-10-18 2023-05-25 The Trustees Of The University Of Pennsylvania Improved adeno-associated virus (aav) vector and uses therefor
WO2022094078A1 (en) 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
TW202233844A (zh) 2020-10-29 2022-09-01 賓州大學委員會 Aav衣殼及含有其之組成物
EP4256065A2 (de) 2020-12-01 2023-10-11 The Trustees of The University of Pennsylvania Neue zusammensetzungen mit gewebespezifischen zielmotiven und zusammensetzungen damit
PH12023551518A1 (en) 2020-12-01 2024-05-13 Akouos Inc Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
PE20240012A1 (es) 2020-12-29 2024-01-04 Akouos Inc Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1
US20250345463A1 (en) 2021-01-30 2025-11-13 Universitat Autònoma De Barcelona Gene therapy for monogenic diabetes
BR112023015303A2 (pt) 2021-02-01 2023-11-14 Regenxbio Inc Método para tratar doença cln2 devido a deficiência de tpp1 em um sujeito
JP2024509792A (ja) 2021-02-26 2024-03-05 武田薬品工業株式会社 ファブリー病の治療のための組成物及び方法
IL307633A (en) 2021-04-12 2023-12-01 Univ Pennsylvania Useful preparations in the treatment of spinal muscular atrophy (SBMA)
EP4326753A2 (de) 2021-04-23 2024-02-28 University of Rochester Genomeditierung durch gerichtete nichthomologe dna-insertion unter verwendung eines retroviralen integrase-cas-fusionsproteins und behandlungsverfahren
EP4089171A1 (de) 2021-05-12 2022-11-16 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Rekombinante tert-codierende virale genome und vektoren
MX2024002408A (es) 2021-08-31 2024-06-19 Scout Bio Inc Moléculas de unión al antígeno y usos de estas.
CA3233097A1 (en) 2021-09-30 2023-04-06 Katherine Diane GRIBBLE Compositions and methods for treating kcnq4-associated hearing loss
WO2023056399A1 (en) 2021-10-02 2023-04-06 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
TW202340467A (zh) 2022-01-10 2023-10-16 賓州大學委員會 有用於治療c9orf72介導之病症之組成物及方法
CN115851837B (zh) * 2022-01-25 2025-12-16 广州派真生物技术有限公司 一种提高杆状病毒系统生产腺相关病毒的方法及应用
JP2025504910A (ja) 2022-01-25 2025-02-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 心臓形質導入の改善及び肝臓の脱標的化のためのａａｖカプシド
EP4473011A1 (de) 2022-02-02 2024-12-11 Akouos, Inc. Anti-vegf-antikörperkonstrukte und zugehörige verfahren zur behandlung von vestibulärem schwannoma-assoziierten symptomen
EP4504950A1 (de) 2022-04-01 2025-02-12 Takeda Pharmaceutical Company Limited Gentherapie für erkrankungen mit zns-manifestationen
US20250215111A1 (en) 2022-04-06 2025-07-03 The Trustees Of The University Of Pennsylvania Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
KR20250044484A (ko) 2022-06-24 2025-03-31 튠 쎄라퓨틱스, 인코포레이티드 표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
US20260021205A1 (en) 2022-07-15 2026-01-22 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
JP2025529884A (ja) 2022-08-25 2025-09-09 武田薬品工業株式会社 ファブリー病の治療に使用するための組成物
WO2024052413A1 (en) 2022-09-07 2024-03-14 Universitat Autònoma De Barcelona Beta-hexosaminidase vectors
WO2024105638A1 (en) 2022-11-18 2024-05-23 Jcr Pharmaceuticals Co., Ltd. Recombinant aav vectors and methods for treatment of hunter syndrome
TW202440939A (zh) 2022-12-17 2024-10-16 賓州大學委員會 具心臟及骨骼肌特異性靶向模體的重組aav突變載體及含有其之組成物
AU2024269420A1 (en) 2023-05-11 2025-11-27 Case Western Reserve University Anxiolytic therapy
TW202516019A (zh) 2023-06-29 2025-04-16 賓州大學委員會 具中樞神經系統靶向模體的突變aav及含有其之組成物
AU2024320694A1 (en) 2023-08-10 2026-02-12 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of spinal muscular atrophy
WO2025102034A1 (en) 2023-11-10 2025-05-15 The Trustees Of The University Of Pennsylvania Gene therapy for barth syndrome
WO2025106661A1 (en) 2023-11-14 2025-05-22 The Trustees Of The University Of Pennsylvania Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
WO2025129157A1 (en) 2023-12-15 2025-06-19 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of canavan disease
WO2025188625A1 (en) 2024-03-03 2025-09-12 Passage Bio, Inc. Recombinant adeno-associated virus for treatment of neurodegenerative disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
ES2220923T3 (es) * 1993-11-09 2004-12-16 Medical College Of Ohio Lineas celulares estables capaces de expresar el gen de replicacion del virus adeno-asociado.
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
EP1983057A3 (de) * 1995-09-08 2009-01-07 Genzyme Corporation Verbesserte AAV-Vektoren für die Gentherapie
US6086913A (en) * 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
WO1998046728A1 (en) * 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production

Also Published As

Publication number Publication date
EP1007637B1 (de) 2004-06-30
US6548286B1 (en) 2003-04-15
EP1007637A4 (de) 2002-04-03
DE69824859T2 (de) 2005-08-04
DE69824859D1 (de) 2004-08-05
JP4249239B2 (ja) 2009-04-02
CA2287478C (en) 2007-06-19
JP2008043349A (ja) 2008-02-28
EP1007637A1 (de) 2000-06-14
AU6974198A (en) 1998-11-11
AU728220B2 (en) 2001-01-04
ES2224375T3 (es) 2005-03-01
JP4135120B2 (ja) 2008-08-20
NZ500546A (en) 2001-09-28
JP2001520516A (ja) 2001-10-30
CA2287478A1 (en) 1998-10-22
WO1998046728A1 (en) 1998-10-22
US7229823B2 (en) 2007-06-12
US20030211614A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
ATE270324T1 (de) Methoden zur erhöhung der effizienz rekombinanter aav produkte
DE69839584D1 (de) Verfahren zur erhöhung der leistungsfähigkeit der rekombinanten aav produktion
Ting et al. The nucleotide sequence encoding the hamster 78-kDa glucose-regulated protein (GRP78) and its conservation between hamster and rat
EE200300332A (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin
Cucchiarini et al. Remodelling of human osteoarthritic cartilage by FGF‐2, alone or combined with Sox9 via rAAV gene transfer
US20020028514A1 (en) Recombinant AAV vector-based transduction system and use of same
CA2338541A1 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
KR960010864A (ko) 동물 세포의 형질 감염을 위한 재조합 dna 바이러스 벡터
DE69535703D1 (de) Aav-vermittelte überbringung von dna in zellen des nervensystems
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
BR9908018A (pt) Adenovìrus modificado contendo uma proteìna de substituição de fibra
Guo et al. Chondrogenic effect of precartilaginous stem cells following NLS‐TAT cell penetrating peptide‐assisted transfection of eukaryotic h TGF β3
DE69828167D1 (de) Rekombinante adenovirale vektoren, die eine spleissequenz enthalten
Moralli et al. Developing de novo human artificial chromosomes in embryonic stem cells using HSV-1 amplicon technology
Fallah et al. Direct reprogramming of fibroblasts to osteoblasts: techniques and methodologies
DE69632201D1 (de) Regulierte expression von proteinen in stabil transformierten säugetierzellen
Yang et al. Adeno-associated virus-mediated bone morphogenetic protein-7 gene transfer induces C2C12 cell differentiation into osteoblast lineage cells
ATE469920T1 (de) Herstellung von rekombinanten igm in den per.c6 zellen
DE69940267D1 (de) Wirtszellen, die rekombinantes humanes erythropoietin exprimieren
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
ATA282386A (de) Verfahren zur expression von genen in hefe und dna-fragmente und diese dna-fragmente enthaltende plasmide zur verwendung bei diesem verfahren
Shen et al. Sustained baculovirus‐mediated expression in myogenic cells
CN111100847A (zh) 安全性更高的端粒基因治疗产品使人体健康逆转衰老
Pruchnic et al. Muscle derived cell mediated ex vivo gene transfer to the lower urinary tract: comparison of viral vectors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties